UPDATE: Morgan Stanley Reiterates Equal-Weight Rating, Removes PT on Regeneron Pharmaceuticals Following Good Results of Drug Study - Regeneron Pharmaceuticals (NASDAQ:REGN)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Regeneron Pharmaceuticals

(NASDAQ: REGN), but removed the $310.00 price target.In the report, Morgan Stanley noted, “Dupilumab (IL-4R antibody) achieved statistical significant reductions of atopic dermatitis (AD) in PhIIb study: Mean changes in placebo-adj EASI score (AD clearance) were 27% (100mg weekly) - 56% (300mg weekly) compared to 51% (300mg weekly) in PhIIa. Safety appeared clean with incr. in colds and headache (also observed in the asthma studies) higher than placebo as well as injection site reactions (5-9.5% vs 3%). As previously planned, PhIII will start in 2H14.”Regeneron Pharmaceuticals closed on Wednesday at $310.93.